OM:EKTA BMedical Equipment
Elekta (OM:EKTA B): Valuation Insights Following New Clinical Evidence Supporting Unity Platform’s Patient Benefits
Elekta (OM:EKTA B) is in focus after new results from the international MOMENTUM study showed its Elekta Unity platform delivers lasting quality of life improvements for men facing localized prostate cancer. The data underscores real-world patient benefits.
See our latest analysis for Elekta.
Over the past year, Elekta’s share price return has been under pressure, sliding 21.3% year-to-date and delivering a one-year total shareholder return of -27.3%. While short-term price momentum has...